[125I]PARPi-01

Radionuclide: I-125 t½ 85666 min
Modality: Therapy
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Breast cancer Apoptosis and early treatment response

What it is

Compound class: PARP inhibitor (Olaparib derivative)
Target / mechanism: PARP1 (Poly ADP-ribose Polymerase 1) PMID 36104637
Clinical application: PARP targeted Auger emitter therapy for triple-negative breast cancer PMID 36104637
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	HPLC+SPE	78 ± 12%	>95%	Tributyl stannylated derivative of Olaparib	36104637 2022 EJNMMI Res Radiolabelling was conducted as previously described [17] - The resulting overall radiochemical yield was 78 ± 12% with purities of > 95%.

Need this precursor?We can point you to suppliers for [125I]PARPi-01, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 36104637. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 36104637: 'Tributyl stannylated derivative of Olaparib'. Stage set/updated at stage 23 from PMID 36104637: 'In this study, a theranostic approach was investigated in a TNBC xenografted mouse model by radiolabelling a close derivative of a PARPi Olaparib (termed PARPi-01) with the Auger emitters 123/125I.'.